Cantor analyst Daniel Brims was out pounding the table on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Thursday, reiterating a Buy rating and price target of $14, …
Thomas Yip, equity research analyst at MLV & Co., weighed in today with a favorable report on Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) increased more than 26% in pre-market trading to $4.
Cantor’s healthcare analyst Daniel Brims came out with a few insights on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), after the company hosted an Analyst and Investor Day on April …
In a research report released Tuesday, MLV analyst Thomas Yip maintained a Buy rating on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) with a $14.
In a research report issued today, MLV analyst George Zavoico reiterated a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $14.50 price target, …
In a research report released Monday, H.C.
In a research note released today, Cantor Fitzgerald analyst Daniel Brims reaffirmed a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $14 price …
In a research note released yesterday, H.C.
In a research report released yesterday, William Blair analyst John Sonnier maintained an Outperform rating on Threshold Pharma (NASDAQ:THLD), in light of the …
